Long-term treatment with piroximone in patients with chronic heart failure.

[1]  J. S. Janicki,et al.  Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. , 1987, American heart journal.

[2]  B. Massie,et al.  Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside. , 1987, The American journal of cardiology.

[3]  R. Arbogast,et al.  Acute Hemodynamic Effects of Piroximone (MDL 19,205) in Patients with Moderate Congestive Heart Failure: Comparison with Sodium Nitroprusside , 1986, Journal of cardiovascular pharmacology.

[4]  J. Cohn,et al.  Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. , 1984, Journal of the American College of Cardiology.

[5]  H. Cheng,et al.  In Vitro and In Vivo Assessment of the Cardiovascular Effects of the Cardiotonic Drug MDL 19205 , 1984, Journal of cardiovascular pharmacology.

[6]  R. C. Dage,et al.  Studies on the Mechanism of the Cardiotonic Activity of MDL 19205: Effects on Several Biochemical Systems , 1984, Journal of cardiovascular pharmacology.

[7]  C. P. Hsieh,et al.  Cardiovascular Properties of a New Cardiotonic Agent, MDL 19205 , 1984, Journal of cardiovascular pharmacology.

[8]  V. Velebit,et al.  Aggravation and Provocation of Ventricular Arrhythmias by Antiarrhythmic Drugs , 1982, Circulation.

[9]  K. Weber.  New hope for the failing heart. , 1982, The American journal of medicine.

[10]  J. Cohn,et al.  Role of vasoconstrictor mechanisms in the control of left ventricular performance of the normal and damaged heart. , 1979, The American journal of cardiology.

[11]  L. Horowitz,et al.  Electrocardiographic Findings in Patients with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy , 1978, Circulation.

[12]  L. Opie,et al.  The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. , 1978, The Journal of clinical investigation.

[13]  L. Opie,et al.  CYCLIC ADENOSINE MONOPHOSPHATE, VENTRICULAR FIBRILLATION, AND ANTIARRHYTHMIC DRUGS , 1976, The Lancet.

[14]  A. Govaerts,et al.  CANCER, ASTHMA, AND CYCLIC A.M.P. , 1975, The Lancet.

[15]  H. Nagasawa,et al.  Cardiotoxicity of alcohol , 1974 .

[16]  J. Cohn,et al.  Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. , 1986, Circulation.

[17]  J. Doherty,et al.  Clinical pharmacology of digitalis glycosides. , 1975, Annual review of medicine.